
Stock·NYSE·Healthcare
AbbVie Inc. (ABBV)
- Market cap
- $505.89B
- P/E
- 49.18
- Dividend yield
- 2.42%
- Street target
- $317.00median of 29 analysts
- 52-week range
- $190.75 $302.93
What moved AbbVie Inc. (ABBV)
Market figures as of November 20, 2026.
Was it the market or the company?
On November 20, 2026, ABBV rose 0.94%. The same day the S&P 500 (SPY) fell 3.64%, the Nasdaq 100 (QQQ) fell 5.67% and the health care sector (XLV) fell 0.12%.
The move was in line with the market. ABBV's one-year beta to SPY is -0.01, so SPY's -3.64% would on average have meant +0.03% for ABBV, close to what it did (0.9 percentage points more).
Over the last 20 sessions ABBV is up 0.20% against -9.23% for SPY, 9.4 percentage points ahead of it.
The wider market on November 20, 2026: CNBC reported that the sell-off's breaking point came with Anthropic's initial public offering and heavier selling in Nvidia, which it named as the first of five forces behind the drop. (CNBC, November 20, 2026)
| That day | 5 sessions | 20 sessions | |
|---|---|---|---|
| ABBV | +0.94% | -2.99% | +0.20% |
| S&P 500 (SPY) | -3.64% | -8.56% | -9.23% |
| Nasdaq 100 (QQQ) | -5.67% | -10.51% | -13.62% |
| Health care sector (XLV) | -0.12% | -6.15% | -1.14% |
Calculated by CleaRank from daily closes. Beta is measured on the last year of daily returns against SPY. A description of what happened, not a forecast.
ABBV stock today, November 22, 2026: price, news and analyst targets
As of November 20, 2026, AbbVie Inc. (ABBV) trades at $286.20. Wall Street's median 12-month price target is $317.00 across 29 analysts, 10.8% above the price. CleaRank rates it Buy with a score of 66/100.
AbbVie shares sit at $286.20, about 5.85% above their 52-week high of $302.93 and above its 50-day and 200-day moving averages ($279.00 and $242.45), while the 20-day exponential average at $288.54 is the first hurdle overhead. The stock slipped 2.99% over the past week after a November 18, 2026 decline of 2.33% that closed at $286.01, so the recent pullback has come from a close near its 52-week peak. Analysts remain constructive, with 23 of 29 rating the stock buy or strong buy, but the valuation is stretched, with a trailing P/E of 49.18 against a sector median of 31.9. That combination of strong trend and rich valuation frames the next few weeks.
Why the trend still favours the stock
AbbVie trades 2.58% above its 50-day simple average and 18.04% above its 200-day average, with the 50-day average itself 15.08% above the 200-day. That alignment of averages is the core of the CleaRank trend reading, which is strongly positive. Over the past year the stock has risen 24.73%, and over six months 32.68%, so the advance has been sustained rather than a single spike. The price has also been close to its high: the November 13, 2026 close of $295.03 was its highest in 52 weeks.
What the recent pullback means
The shares are down 2.99% over the past week and fell 2.33% on November 18, 2026, closing at $286.01. The move was larger than the stock's typical daily swing of 1.43%, though the 30-day standard deviation is a backward-looking measure. The stock also fell 2.05% in the first session after the October 30, 2026 report, despite the EPS beat. Three of the four most recent earnings reports were followed by a lower first-session price, so investors have sold into good numbers before. Against this, the 20-day average is still the first ceiling, and the MACD line is positive, which suggests the momentum behind the trend has not yet turned.
Valuation is the main drag
At a trailing P/E of 49.18, AbbVie trades at a premium to peers, 54.2% above the sector median of 31.9. The price-to-sales ratio of 7.73 is 127.2% above the sector median of 3.4. Trailing GAAP earnings of $5.82 per share underpin that multiple, and analysts expect this fiscal year's EPS to reach $13.98 on their adjusted basis, a 39.8% rise. Revenue grew 10.16% in the latest quarter year on year, faster than the sector median of 8.1% by 2.1 percentage points, and the operating margin of 36.64% is high. The business is growing faster than its peers, but the price already reflects a great deal of that growth.
Insider selling and analyst support
Insiders sold $41.9M of stock over the last 18 months across seven sales, with no open-market purchases. Such sales are often planned in advance or made to cover tax on vesting shares, so they carry less weight than buying. On the analyst side, 23 of 29 ratings are buy or strong buy, 5 are hold and 1 is sell, and the median 12-month target is $317.00, 10.8% above the price. Three months ago 25 of 31 ratings were buy, so the share of buy ratings has risen slightly.
CleaRank score 66/100 (Buy). 15 of 19 checks pass: trend 4 of 4, momentum 2 of 3, valuation and quality 3 of 5, analysts 2 of 3, track record 4 of 4.
About AbbVie
AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and commercializes medicines and therapies for complex and serious diseases. AbbVie focuses on major therapeutic areas including immunology, oncology, neuroscience, eye care, aesthetics, and virology, serving patients with chronic autoimmune conditions, blood cancers, inflammatory disorders, and other specialized medical needs. The company’s portfolio includes branded prescription medicines and advanced therapies distributed through physicians, wholesalers, specialty pharmacies, healthcare facilities, and other healthcare channels.
ABBV stock news
Earnings beat
Earnings report, October 30, 2026
The October 30, 2026 report beat the EPS estimate by 1.60%, and the share price fell 2.05% in the first session after it.
Rating reaffirmed
Analyst action, UBS, November 2, 2026
UBS kept its Neutral rating on November 2, 2026.
ABBV price target 2026
The base case is that AbbVie holds above its 50-day average at $279.00 and works back toward the 20-day average and then the 52-week high, provided revenue keeps growing near the 10.16% pace of the latest quarter and margins stay high. The analysts' median 12-month target of $317.00 implies room to run if the company keeps meeting estimates, which it has done in each of its last four reports. The bullish case strengthens on a close above the November 13, 2026 high of $295.03 and a move through the $302.93 52-week high. The bearish case rests on the valuation: a loss of the 50-day average would bring the 200-day average at $242.45 into view, and slower growth against a P/E of 49.18 would make a premium that is hard to sustain. Analysts' estimates call for EPS growth of 39.8% this fiscal year and 15.8% next year, so the earnings path matters more than the price action in the short term.
Analyst targets and ratings
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 2, 2026 | UBS | Maintains | Neutral |
| Nov 2, 2026 | Leerink Partners | Maintains | Outperform |
| Nov 2, 2026 | Morgan Stanley | Maintains | Overweight |
| Nov 2, 2026 | Guggenheim | Maintains | Buy |
| Nov 2, 2026 | Wells Fargo | Maintains | Overweight |
| Nov 2, 2026 | RBC Capital | Maintains | Outperform |
ABBV support and resistance levels
Support sits at $279.00, the 50-day simple moving average, the nearest level below the price; a close beneath it would signal the uptrend losing its footing. The next support is the 200-day simple moving average at $242.45, which the stock has held comfortably for months. The third support is the 52-week low of $190.75. Resistance starts at the 20-day exponential moving average at $288.54, a level the price sits just under and that has to be reclaimed for short-term momentum to improve.
| Level | What it is | Price | From the price |
|---|---|---|---|
| Resistance 2 | 52-week high | $302.93 | +5.8% |
| Resistance 1 | 20-day exponential average | $288.54 | +0.8% |
| Price | November 20, 2026 | $286.20 | |
| Support 1 | 50-day moving average | $279.00 | -2.5% |
| Support 2 | 200-day moving average | $242.45 | -15.3% |
| Support 3 | 52-week low | $190.75 | -33.4% |
Technical indicators
ABBV technical analysis in depth
Volatility, momentum, trend strength and the price levels that matter for ABBV, calculated by CleaRank from daily bars to November 20, 2026.
Volatility
On the 20-day Bollinger Bands (2 standard deviations) the bands run from $282.66 to $298.22 around a middle of $290.44, and ABBV's close of $286.20 sits inside the bands, away from both edges.
The bands are narrower than on 94% of the last 120 sessions: a squeeze, the kind of quiet stretch that has often come before a larger move in either direction.
The 14-day average true range is $6.703, or 2.3% of the price: a typical day's swing from high to low. A stop placed 1.5 ATR away would sit about 3.5% from the close.
Momentum and volume
The 14-day stochastic reads 27 (signal line 22): the close is in the middle of its two-week range.
The MACD line (12, 26) is 2.48 against a signal line (9) of 4.22, so the histogram is negative: momentum is weakening relative to its recent average. The MACD line crossed below its signal line 13 sessions ago.
Volume in the latest session was 1.7 times its 20-day average, heavy enough to give the move more weight.
Trend strength
The 14-day ADX is 25: a trending market, with buyers in control (+DI 28, -DI 24).
On the weekly chart the 10-week average ($280.61) is above the 40-week average ($243.28), a rising longer-term trend, and the weekly RSI is 65.
Key levels
The nearest resistance from the price history is $291.40 (+1.8%): a swing high set on October 15, 2026.
The nearest support is $279.54 (-2.3%): the price turned here 2 times, most recently on November 6, 2026.
The largest swing of the last 120 sessions ran up from $213.73 (June 3, 2026) to $302.93 (November 5, 2026); the nearest Fibonacci retracement to the price is the 23.6% level at $281.88.
Classic pivot points for the next session, from November 20, 2026: pivot $287.09, resistance $289.34 and $292.47, support $283.96 and $281.71.
| Level | Price | From the price | What it is |
|---|---|---|---|
| Resistance (swing high) | $302.93 | +5.8% | a swing high set on November 5, 2026 |
| Upper Bollinger Band | $298.22 | +4.2% | 20-day average + 2 standard deviations |
| Pivot R2 (classic) | $292.47 | +2.2% | next-session level |
| Resistance (swing high) | $291.40 | +1.8% | a swing high set on October 15, 2026 |
| Pivot R1 (classic) | $289.34 | +1.1% | next-session level |
| Pivot R1 (Fibonacci) | $289.15 | +1.0% | 38.2% of the last range above the pivot |
| Pivot point | $287.09 | +0.3% | average of the last high, low and close |
| Price | $286.20 | close, November 20, 2026 | |
| Pivot S1 (Fibonacci) | $285.04 | -0.4% | 38.2% of the last range below the pivot |
| Pivot S1 (classic) | $283.96 | -0.8% | next-session level |
| Lower Bollinger Band | $282.66 | -1.2% | 20-day average - 2 standard deviations |
| Fibonacci 23.6% | $281.88 | -1.5% | retracement of the rise from $213.73 to $302.93 |
| Pivot S2 (classic) | $281.71 | -1.6% | next-session level |
| Support (swing low) | $279.54 | -2.3% | the price turned here 2 times, most recently on November 6, 2026 |
| Fibonacci 38.2% | $268.86 | -6.1% | retracement of the rise from $213.73 to $302.93 |
| Support (swing low) | $267.94 | -6.4% | the price turned here 3 times, most recently on September 23, 2026 |
| Support (swing low) | $261.18 | -8.7% | the price turned here 4 times, most recently on October 2, 2026 |
| Fibonacci 50.0% | $258.33 | -9.7% | retracement of the rise from $213.73 to $302.93 |
| Fibonacci 61.8% | $247.80 | -13.4% | retracement of the rise from $213.73 to $302.93 |
| Fibonacci 78.6% | $232.82 | -18.7% | retracement of the rise from $213.73 to $302.93 |
Swing levels are highs and lows the price turned at (the extreme of the five sessions either side), merged when they sit within 1.2 average true ranges of each other. Bollinger Bands (20, 2), ATR (14, Wilder), stochastic (14, 3), MACD (12, 26, 9), ADX (14, Wilder). Readings describe the chart; they are not a forecast.
ABBV stock price and trading
ABBV share price
ABBV fundamentals and valuation
Key statistics
ABBV against the Healthcare sector
Price to earnings vs sector: ABBV trades at a significant premium to sector peers (+54% against the sector median P/E). Investors are paying more for each dollar of earnings than for the typical stock in the sector.
Return vs XLV: Since Jun 11, 2025, ABBV has gained 49.5% against a gain of 30.6% for XLV.
Performance against XLV
Revenue and earnings
Revenue growth: Revenue grew 8.6% in FY2025 to $61.2B, from $56.3B a year earlier.
Profit margin: The net margin was 6.9% in FY2025, down from 7.6% the year before.
Profitable: ABBV earned $4.2B in FY2025.
Earnings reality check
Earnings record: ABBV beat the analyst estimate in 4 of the 4 reports in our data.
Market reaction: The stock fell in the first session after 3 of those 4 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Oct 30, 2026 | $3.76 | $3.82 | +1.60% | -2.05% | -1.21% |
| Jul 31, 2026 | $3.61 | $3.65 | +1.11% | -2.33% | -1.95% |
| Feb 4, 2026 | $2.65 | $2.71 | +2.26% | +0.88% | +1.74% |
| Oct 31, 2025 | $1.78 | $1.86 | +4.49% | -2.79% | +0.51% |
ABBV price history and drawdowns
Risk profile
Worst falls and recoveries
Growth of $10,000
Against the market: ABBV beat the S&P 500 over this period: $72,285 against $36,764.
A $10,000 investment in ABBV in December 2016 would be worth about $72,285 today with dividends reinvested, compared with about $36,764 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
ABBV stock price prediction 2030
ABBV Stock Price Prediction 2030: Simulated Scenarios
CleaRank's simulation projects a price near $415 for ABBV by 2030 in the base case, from $286 today (1.4x over 4 years). The 10th-percentile path ends near $212. These are outcomes of a Monte Carlo simulation run on ABBV's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $225 | $314 | $439 | |
| 2028 | $215 | $344 | $553 | |
| 2029 | $212 | $378 | $675 | |
| 2030 | $212 | $415 | $810 |
ABBV insider trading
ABBV insider trading
Month by month
Net insider selling: No insider bought ABBV shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Nov 12, 2026 | Jeffrey Ryan Stewart
Officer
|
Grant | 3.5K | - |
| Nov 9, 2026 | Jeffrey Ryan Stewart
Officer
|
Sell | 40.6K | $11.9M |
| Nov 9, 2026 | Jeffrey Ryan Stewart
Officer
|
Option | 40.6K | $4.1M |
| Aug 14, 2026 | Nicholas Donoghoe
Officer
|
Sell | 32.7K | $8.2M |
| Aug 14, 2026 | Nicholas Donoghoe
Officer
|
Option | 32.7K | $2.6M |
| May 8, 2026 | Roxanne Schuh Austin
Director
|
Grant | 1.1K | - |
| May 8, 2026 | William H L Burnside
Director
|
Grant | 1.1K | - |
| May 8, 2026 | Jennifer L Davis
Director
|
Grant | 1.1K | - |
| May 8, 2026 | Thomas J Falk
Director
|
Grant | 1.1K | - |
| May 8, 2026 | Thomas C Freyman
Director
|
Grant | 1.1K | - |
ABBV stock forecast: questions people ask
ABBV Forecast: Frequently Asked Questions
What is the ABBV stock forecast?
What is the ABBV price target?
Is ABBV a buy or sell today?
How does AbbVie's valuation compare with peers?
How has AbbVie performed in its recent earnings reports?
What does the dividend look like?
How has the stock performed over the past year?
How these figures are computed, and where the data comes from: CleaRank methodology.